UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2024
COMMISSION FILE NUMBER 001-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On August 29, 2024, MorphoSys AG (the “Company”) published the half-year report January – June 2024 attached hereto as Exhibit 99.1.
Exhibit 99.1 to this report on Form 6-K is incorporated by reference, other than the information under the Sections “Proprietary Clinical Development” on pages 7-9 and “Financial Guidance” on page 17-18, in the registration statement on Form S-8 (File No. 333-277693) of MorphoSys AG and in the outstanding prospectus contained in such registration statement.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant)
Date: August 29, 2024 By: /s/ i.A. Isabelle Degbegni
Name: Isabelle Degbegni
Title: Director Investor Relations
By: /s/ i.A. Dr. Robert Mayer
Name: Dr. Robert Mayer
Title: Director Investor Relations
